These findings have been confirmed by the observed rebound effect following long-term anti-VEGF therapies with RTK blockers in cancer patients, including a case series of dasatinib-induced PAH, and the increased transcription and overexpression of growth factor receptors genes and proteins, respectively. This evidence concerns the gene VEGFA and pulmonary arterial hypertension.